Drug with Active Ingredient Nusinersen 12 Mg Tender - 142711279

Procurement Summary

Country: Slovakia

Summary: Drug with Active Ingredient Nusinersen 12 Mg, Injection Solution Description: the Subject of the Order is the Medicine Nusinersen 12 Mg Injection Solution Supplement: Sol Inj 5 Ml/12 Mg (Liek.Inj.Skl.) Administration:.....

Deadline: 10 Jul 2026

Posting Date: 05 Jun 2026

Other Information

Notice Type: Tender

TOT Ref.No.: 142711279

Document Ref. No.: 7782 - MST

Competition: ICB

Financier: Self Financed

Purchaser Ownership: Public

Tender Value: EUR 3892818.4

Purchaser's Detail

Name: Login to see tender_details

Address: Login to see tender_details

Email: Login to see tender_detailsLogin to see details

Tender Details

DRUG WITH ACTIVE INGREDIENT NUSINERSEN 12 MG, SOLUTION FOR INJECTION Description: The subject of the order is the drug NUSINERSEN 12 MG SOLUTION FOR INJECTION Supplement: salt inj 5 ml/12 mg (liek.inj.skl.) Administration: intrathecal use One vial with a volume of 5 ml contains sodium salt of nusinersen, which corresponds to 12 mg of nusinersen. One ml contains 2.4 mg of nusinersen. Nusinersen is an antisense oligonucleotide (antisense oligonucleotide, ASO) that increases the proportion of exon 7 inclusion in messenger ribonucleic acid transcripts ribonucleic acid, mRNA) for SMN2 (survival motor neuron 2, SMN2) by binding to the intronic splice silencing site (ISS-N1) located in intron 7 of the SMN2 pre-messenger ribonucleic acid (pre-messenger ribonucleic acid, pre-mRNA) for SMN2. ASO by this connection it displaces splicing factors that suppress splicing under normal circumstances. Displacement of these factors results in the retention of exon 7 in SMN2 mRNA, and therefore when SMN2 mRNA is produced, it can be transcribed into a functional full-length SMN protein. A drug with an active ingredient Nusinersen is indicated for the treatment of 5q spinal muscular atrophy. Treatment with this medicine should only be started by a doctor with experience in spinal muscular atrophy (SMA). The decision to treat must be based on an individualized professional evaluation expected benefits of treatment for a specific patient balanced with respect to the potential risk of drug treatment. In patients with compulsory hypotonia and respiratory failure at birth, in whom this drug has not been studied, it may not be due to compulsory deficiency of the SMN protein to show a clinically significant yield. The recommended dose is 12 mg (5 ml) per administration. Treatment must be started as soon as possible after diagnosis with 4 loading doses on days 0, 14, 28 and 63. A maintenance dose should then be administered every 4 months. Kind of orders: Goods 4.1.3 Scope of procurement Estimat...
Deadline for submission of bids: (date): 10.07.2026 Deadline for submission of bids (time): 09:00 Binding of the bid Deadline, until which the bid must remain binding Deadline, until which the bid must remain binding (BT-98-Lot) (value): 4 Deadline, until which the bid must remain binding (BT-98-Lot) (unit): Month Language of bids Language of bids Language in which bids can be submitted: Slovak Language of bids Language in which bids can be submitted: čestina Information on opening of bids Date of opening of bids: 10.07.2026 Bid opening time: 10:00 Place of bid opening: electronically Method of submitting bids or requests to participate Electronic bid submission: Mandatory Address for submitting bids (URL): https://www.isepvo.sk Information on competition documents Information on competition materials Competition materials in official languages ​​Competition materials in official language Competition materials in official language Official language of competition materials: Slovak Restricted access to competition materials: No restrictions on access to by document Competition documents (URL): https://www.uvo.gov.sk/vyhladavanie/vyhladavanie-zakaziek/dokumenty/558919 Designation of document/contract: Competition documents Communication channel ad hoc Name of electronic means: IS EVO Review Deadlines for review Description deadline for review: Deadlines for submitting objections are governed by the valid and effective law on public procurement. Review Organization ID of the organization responsible for the review: ORG-0001 (Public Procurement Office) Organization providing information on reviews ID of the provider of information about the review: ORG-0001 (Public Procurement Office) Procurer Profile Order: DRUG WITH ACTIVE SUBSTANCE NUSINERSEN 12 MG, INJECTION SOLUTION Procurement...

Documents

 Tender Notice